Reply to marr et al

Clinical Infectious Diseases

Volumn 49, Issue 7, 2009, Pages 1139-1140

  Cordonnier, Catherine ^a,b,e   Schwarzinger, Michael ^c,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c Institut National de la Sante   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e Hematology Department   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT;

CANDIDEMIA; DISEASE DURATION; EVIDENCE BASED MEDICINE; GENETIC ANALYSIS; HUMAN; INFECTION RISK; LETTER; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME;

EID: 70349929465     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605602     Document Type: Letter

References (2)

1. Cordonnier C, Pautas C, Maury S, et al. Empiric versus pre-emptive antifungal therapy for high-risk, febrile neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042-1051
2. Marr KA, Leisenring W, Bow E. Empirical versus preemptive antifungal therapy for fever during neutropenia [letter]. Clin Infect Dis 2009; 49:1138-1139 (in this issue).